Q-linea today announces that the company has finished the clinical trials for the drug Meropenem-Vaborbactam with strong results and is therefore able to claim IVDR compliance and add the drug to the existing BC-GN panel. The company expects commercial availability in
Meropenem-Vaborbactam is a combination drug of a Carbapenem and a beta-lactamase inhibitor with enhanced activity against gram-negative organisms, particularly Enterobacterales with class A and C carbapenemases.
"This is an important step in our continuous strive to offer the best product for our customers. The use of antibiotic combinations has become increasingly important for treatment and Meropenem-Vaborbactam is another important addition to our panel to fight resistant bacteria. We believe that the addition will be well received by our customers helping them providing the best possible treatment for patients with blood stream infections," said Jonas Jarvius, CEO and President at Q-linea.
© Modular Finance, source